The information you provided is not the full article, but only a correction (errata) published in the 2025 Lancet. The correction relates to the ANCHOR-1 and ANCHOR-2 studies that investigated the efficacy and safety of twice-yearly depemokimab in chronic rhinosinusitis with nasal polyps. In the Results section, the sentence regarding the number of participants who received depemokimab was corrected. In Appendix 1, the value ranges for the sensitivity analyzes regarding nasal polyp (NPS) and verbal nasal obstruction scale score (VRS) were updated. The corresponding Figure S12 has also been modified accordingly. Without access to the full text of the article, I cannot provide a detailed summary of the main findings of the studies.